May, 2017

CURRICULUM VITAE

MARTIN L. OGLETREE, PH.D.

Current Positions: Adjunct Professor of Pharmacology
Vanderbilt University School of Medicine
442 Robinson Research Building; Nashville, TN 37232
martin.ogletree@vanderbilt.edu

Owner, Points & Assists, LLC
martin.ogletree@verizon.net

Chair, Professional Affairs Committee
Jeanes Hospital Board of Directors
Member, Quality and Professional Affairs Committee
Temple University Health System
Philadelphia, PA 19140

Home Address: 12 Llanberris Road
P.O. Box 559
Bala Cynwyd, PA 19004
Phone: (610) 664-3976 Mobile: (267) 981-1296

Education:

1970-1973 — Swarthmore College, Swarthmore, PA
B.A. in Biology (Bioengineering Emphasis)

1975-1978 — Thomas Jefferson University, Philadelphia, PA
Ph.D. in Physiology (Cardiovascular Emphasis)
Thesis: Actions of Prostaglandins in Normal and Ischemic Heart

1978-1980 — Vanderbilt University, Nashville, TN
Post-doctoral Fellowship (Pulmonary Circulation Emphasis)

Memberships in Scientific and Professional Societies:

American Heart Association
- Council on Arteriosclerosis, Thrombosis and Vascular Biology
- Council on Basic Cardiovascular Sciences
- Council on Cardiopulmonary, Perioperative and Critical Care

European Society of Cardiology
- Thrombosis Working Group

International Society on Thrombosis and Haemostasis

Community Activities:

Anna T. Jeanes Foundation Board, 2010 – present
Corporation of Haverford College, 1974 – present
Newtown Friends Meeting (Quaker), 1983 – present
- Clerk (Executive Officer), 2007 – 2008

Newtown Township Inspector of Elections, 2008 – 2010
Snipes Farm and Education Center Board, 2008 – 2010
George School Committee, 1988 – 2000
- Clerk - Physical Plant Subcommittee, 1990 – 1998

Corporation of Friends Hospital, 1990 – 1998

Selected Research and Professional Experience:

2012 - 2013	Director, Thrombosis Biology Research
2011- 2012	Cardiovascular Franchise, Thrombosis Site Lead
2011	Cardiovascular Franchise, Target Identification and Validation Lead Merck & Co., Inc. Rahway, NJ 07065
2009 - 2011	Director of Development, Cumberland Pharmaceuticals, Inc.
2009 - 2011	Leader of HEPATOREN Product Development Team
2009 - 2010	Prepared initial IND (eCTD) for Acetadote EF (acetylcysteine for injection)
2009 - 2010	Prepared scientific rationale for Acetadote acute liver failure sNDA Cumberland Pharmaceuticals, Inc. Nashville, TN 37203
2002- 2007	Distinguished Research Fellow Metabolic and Cardiovascular Drug Discovery Bristol-Myers Squibb Pharmaceutical Research Institute Hopewell, NJ 08534
2001- 2007	Director – Thrombosis Biology Research
2007- 2007	Member – Apixaban Full Development Research Team
2006- 2007	Member – Apixaban Communications Team
2004- 2007	Member – PLAVIX Core Strategy Team
2003- 2007	Member – Apixaban Full Development Team
2002- 2007	Member – CV & Metabolic Disease Strategy Team
2001- 2007	Leader – Coagulation Early Development Team
2001- 2007	Member – Hopewell Biology Senior Leadership Team
2001- 2007	Member – Hopewell Biology Licensing Team
2001- 2007	Member – Hopewell Biology Patents Team
2002-2003	BMS Representative – Industrial Research Institute
2002-2003	Member – Omapatrilat Full Development Core Team
2001	Member – Clinical Platform Team (DuPont Pharma)
2001	Member – Factor Xa Transition Team (DuPont Pharma)
2001	Leader – Coagulation Stream Teams (DuPont Pharma Integration)
2001	Member – DuPont Pharma Due Diligence Team
2001	Member – DP3-DP5 Process Team (Clinical Dose Selection Process Team)
2001	Member – Clinical Discovery Technologies Design Team
2000-2006	Member – CV Unrestricted Grants Internal Selection Committee, BMS Freedom to Discover Program
2000	Co-Leader – In Vivo Lead Optimization Teams
2000	Co-Leader – Biomarker Discovery Team
2000	Co-Leader – IND Team (Electronic Regulatory Filings)
1999-2006	Member – Target Validation Committee
1999-2003	Manager – Cerep Cardiovascular Alliance
1999-2000	Leader – BMS-344577 Project Working Group
1999-2000	Member – Optimizing Candidate Success Steering Com.
1999	Co-Leader – OCS Toxicology Team
1998-2003	Manager – Harvard School of Public Health CV Alliance
1998-1999	Member – BMS-262084 Project Working Group
1997-2001	Director, Vascular Biology Department
1996-1999	Member – Lanoteplase Project Working Group
1996-1998	Leader – BMS-234101 Project Working Group

Selected Research and Professional Experience (Continued):

1996-1997	Leader – BMS-189664 Project Working Group
1996-1997	Member – Beraprost Assessment Team
1996-1997	Member – COX-2 Inhibitor Working Group
1996	Initiator – Thrombo(ly)sis Focus Group
1995-1998	Member – Protein Tyrosine Kinase Working Group
1994-1998	Chair – Pulmonary Focus Group
1993-1998	Member – Phospholipase Working Group
1991-1997	Research Fellow / Thrombosis Program Coordinator
1991-1996	Member – Ifetroban (BMS-180291) Project Working Group
1991-1996	Co-Chair – Antithrombotics Working Group
1991-1995	Member – Adhesion Molecules Working Group
1991-1994	Member – Endothelin Working Group
1990-1991	Senior Principal Scientist
1986-1991	Head, Eicosanoid Research Section and Working Group
1984-1990	Research Group Leader
1983-1984	Research Fellow, Department of Pharmacology Squibb Institute for Medical Research Princeton, NJ 08543-4000
1980-1983	Assistant Professor of Medicine and Pharmacology
1980-1983	Investigator, Pulmonary Circulation Center
1978-1980	Research Fellow, Pulmonary Circulation Center, Vanderbilt University Medical Center, Nashville, TN 37232
1974-1978	Research Assistant, Pre-doctoral & Post-doctoral Fellow Department of Physiology, Thomas Jefferson University, Philadelphia, PA 19107
1972-1973	Volunteer Surgical Research Assistant Harrison Department of Surgical Research Hospital of the University of Pennsylvania, Philadelphia, PA

Selected Awards:

1975-1980	NIH Predoctoral Fellowship Award and Young Investigator Award
1983	C.K. Drinker Award of the Lung Water Club (American Physiological Society)
1987	Squibb Quality Productivity Award for establishing an electronic network linking biologists and chemists
2000	Bristol-Myers Squibb President's Award for BMS-189664 Formulation Team
2001	Bristol-Myers Squibb President's Award for the work of the Lanoteplase Clinical Development Team
2002	Bristol-Myers Squibb President's Award for work on the acquisition and integration of DuPont Pharmaceuticals
2002	Bristol-Myers Squibb Triumph Award for the work of the Target Validation Committee to develop a global target validation strategy
2012	Merck Outstanding Service for leadership of the CV thrombosis group

Selected Scientific Advisor and Reviewer Roles:

Cyvernetics Strategic Alliance; Cloud Pharmaceuticals Advisory Board; ARKAY Pharmaceuticals Scientific Advisory Board; TechTeams Accelerator Platform Catalyst; Biomedical Engineering Industrial Advisory Board, Vanderbilt University; Specialized Clinical Center of Research Advisory Board, Vanderbilt University; University of Medicine and Dentistry of New Jersey Internal Grants Reviewer; Cardiovascular Study Section, NHLBI; Peer reviewer for Journal of Pharmacology and Experimental Therapeutics, European Journal of Pharmacology, and others

Selected Symposia:

Symposium to Honor Recipients of the 12th Annual Bristol-Myers Squibb Award for Distinguished Achievement in Cardiovascular Research – June 25, 2002; Bristol-Myers Squibb Foundation, Hopewell, NJ - Organizer

Keynote Address: Identifying and Evaluating the Driving Forces Behind Drug Discovery - April 27, 1998; IBC UK Conferences Ltd, Strategic Management of Drug Discovery, London, England

Introduction: Thrombin Modulation in the Development of New Antithrombotic Drugs; and Ifetroban - An Oral, Long-Acting Thromboxane Receptor Antagonist - October 24, 1995; International Business Communications' Sixth International Symposium on Anticoagulant, Antithrombotic and Thrombolytic Drugs, Washington, D.C.

Thrombin-Receptor and Intracellular Signal Transduction - November 29, 1994; Sandoz Foundation Symposium on the Endothelial Cell in Health and Disease, Nürnberg, Germany

Thrombin Receptor Targeting in the Quest for New Antithrombotic Agents - October 24, 1994; International Business Communications' Fifth International Symposium on Anticoagulant, Antithrombotic and Thrombolytic Drugs, Boston, MA

Clinical Targets for Thromboxane Antagonists: Ifetroban - September 16, 1994; The Future of Clinical Drug Developments - German Society for Clinical Pharmacology, Hanover, Germany

Cardiovascular Functions of Thrombin Receptors - July 9, 1993; Satellite Symposium of the XIVth Congress of the International Society on Thrombosis and Hemostasis, New York, NY - Organizer

Lipids, Atherosclerosis and Thrombosis - New Aspects and Sites for Pharmacological Intervention - October 25, 1990; MidAtlantic Pharmacological Society, Princeton, NJ - Co-Organizer

Characterization of Primate Platelet TxA_2/PGH_2 Receptors and Antithrombotic Effects of Receptor Antagonism - August 20, 1989 ISTH Subcommittee on Animal Models of Hemorrhagic and Thrombotic Diseases, Tokyo, Japan

Thromboxane - January 19, 1989; Winter Prostaglandin Conference, Keystone, Colorado - Organizer and Chair

Biochemical Pharmacology of TxA_2 in Health and Disease- February 25, 1986; New York Academy of Sciences - Co-organizer.

New Concepts in the Management of Adult Respiratory Distress Syndrome - November 10, 1985; Cardiopulmonary Council of the American Heart Association, Washington, DC.

Selected Patents:

Recent patent applications published: CA2805110, US20130197044, WO2012009545, EP2593541, US20150297571

Allowed US Patents

Novel combination of an ADP-receptor blocking antiplatelet drug and a thromboxane A2 receptor antagonist and a method for inhibiting thrombus formation employing such combination
Patent Application: US20030109543 A1; Patent Number: 6509348
Publication Date: 12-Jun-2003
Inventor: Ogletree, Martin L.
Assignee: Bristol-Myers Squibb Company

Method of treating dysmenorrhea employing an interphenylene 7-oxabicycloheptyl substituted heterocyclic amide prostaglandin analog
Patent Number: US5605917
Publication Date: 25-Feb-1997
Inventor: Ogletree, Martin L.
Assignee: Bristol-Myers Squibb Company

7-oxabicycloheptyl substituted heterocyclic amide prostaglandin analogs
Patent Number: US5162352
Publication Date: 10-Nov-1992
Inventor: Hall, Steven E.; Ogletree, Martin L.
Assignee: E. R. Squibb & Sons, Inc.

Method of protecting against and/or treating ulcerative gastrointestinal conditions using a thromboxane A2 receptor antagonist and combination useful in preventing and/or treating ulcers and/or inflammation
Patent Number: US5312818; EP0448274 A2
Publication Date: 25-Sep-1991
Inventor: Rubin, Bernard; O'Keefe, Eugene H.; Ogletree, Martin L.; Aberg, Gunnar A.K.
Assignee: E.R. Squibb & Sons, Inc.

Method of preventing or reducing adverse reactions to protamine using a thromboxane A2 receptor antagonist
Patent Number: US5066480; EP0337697 A2; EP0337697 B1
Publication Date: 18-Oct-1989
Inventor: Ogletree, Martin L.; Grover, Gary J.; Schumacher, William A.; Friedhoff, Lawrence T.
Assignee: E.R. Squibb & Sons, Inc.

Method of inhibiting onset of or treating migraine headache using a thromboxane A2 receptor antagonist
Patent Number: US4839384; EP0362587 A2
Publication Date: 13-Jun-1989
Inventor: Ogletree, Martin L.
Assignee: E. R. Squibb & Sons, Inc.

Method of preventing or treating toxemia in pregnancy using a thromboxane A2 receptor antagonist
Patent Number: US4808627; EP0320935 A2
Publication Date: 28-Feb-1989
Inventor: Ogletree, Martin L.
Assignee: E. R. Squibb & Sons, Inc.

BIBLIOGRAPHY

120 Publications in Peer Reviewed Journals:

1. Ogletree, M. L., Beardsley, A. C., Lefer, A. M. Myocardial actions of prostaglandins in isolated cat cardiac tissue. Life Sci. 16: 1923 - 1930, 1975.

2. Carlson, R. P., Ogletree, M. L., Lefer, A. M. Actions of leukocytic inflammatory substance on isolated tissue responses. Proc. Soc. Exp. Biol. Med. 150: 52 - 56, 1975.

3. Ogletree, M. L., Lefer, A. M. Influence of non-steroidal anti-inflammatory agents on myocardial ischemia in the cat. J. Pharmacol. Exp. Ther. 197: 582 - 593, 1976.

4. Spath, J. A., Jr., Ogletree, M. L., Lefer, A. M. Lack of a significant protective effect of augmented circulating glucose on the ischemic myocardium. Can. J. Physiol. Pharmacol. 54:423 - 429, 1976.

5. Ogletree, M. L., Flynn, J. T., Feola, M., Lefer, A. M. Early prostaglandin release from the ischemic myocardium in the dog. Surg. Gynecol. Obstet. 144: 734-740, 1977.

6. Lefer, A. M., Okuda, M., Ogletree, M. L. Tissue uptake of ^{3}H-methylprednisolone in acute myocardial ischemia. J. Thorac. Cardiovasc. Surg. 74: 37-43, 1977.

7. Ogletree, M. L., Lefer, A. M. Prostaglandin-induced preservation of the ischemic myocardium. Circ. Res. 42: 218-224, 1978.

8. Lefer, A. M., Ogletree, M. L., Smith, J. B., Silver, M. J., Nicolaou, K. C., Barnette, W. E, Gasic, G. P. Prostacyclin: Profile of a potentially valuable agent for preserving jeopardized myocardial tissue in acute myocardial ischemia. Science 200: 52-54, 1978.

9. Ogletree, M. L., Smith, J. B., Lefer, A. M. Actions of prostaglandins on isolated perfused cat coronary arteries. Amer. J. Physiol. 235: H400 - H406, 1978.

10. Grieco, P. A., Yokoyama, Y., Nicolaou, K. C., Barnette, W. E., Smith, J. B., Ogletree, M. L., Lefer, A. M. Total synthesis of 14-fluoro-prostaglandin F_2 and 14-fluoroprostacyclins. Chem. Letters 1001-1004, 1978.

11. Nicolaou, K. C., Barnette, W. E., Magolda, R. L., Grieco, P. A., Owens, W., Wang, C. L. J., Smith, J. B., Ogletree, M. L., Lefer, A. M. Synthesis and biological properties of 12-fluoroprostacyclins. Prostaglandins 16: 789-794, 1978.

12. Smith, J. B., Ogletree, M. L., Lefer, A. M., Nicolaou, K. C. Antibodies which antagonize the effects of prostacyclin. Nature 1274: 64-65, 1978.

13. Ogletree, M. L., Lefer, A. M., Smith, J. B., Nicolaou, K. C. Studies on the protective effect of prostacyclin in acute myocardial ischemia. Eur. J. Pharmacol. 56: 95-101, 1979.

14. Smith, E. F. Ogletree, M. L., Sherwin, J. R., Lefer, A. M. Effects of prostaglandins on distribution of blood flow in the cat. Prostaglandins and Medicine 1: 411-418, 1978.

15. Ogletree, M. L., Brigham, K. L. Arachidonate raises vascular resistance but not permeability in lungs of awake sheep. J. Appl. Physiol. 48: 581-586, 1980.

16. Brigham, K. L., Ogletree, M. L. Effects of prostaglandins and related compounds on lung vascular permeability. Bulletin European de Physiopathologic Respiratoire 17: 703-722, 1981.

17. Ogletree, M. L. Pharmacology of prostaglandins within the pulmonary circulation. Ann. N. Y. Acad. Sci. 384: 191 - 206, 1982.

18. Brigham, K. L., Loyd, J. E., Newman, J. H., Snapper, J. R., Ogletree, M. L., English, D. K. Granulocytes in acute lung vascular injury in unanesthetized sheep. Chest 81S: 56S - 57S, 1982.

19. Ogletree, M. L., Brigham, K. L. Effects of cyclooxygenase inhibitors on pulmonary vascular responses to endotoxin in unanesthetized sheep. Prostaglandins, Leukotrienes and Medicine 8: 489 - 502, 1982.

20. Ogletree, M. L., Brigham, K. L. Pulmonary vascular and hemodynamic effects of PGE_1 in unanesthetized sheep. Microcirculation, Endothelium and Lymphatics 1: 307 – 327, 1984.

21. Ogletree, M. L., Oates, J. A., Brigham, K. L., Hubbard, W. C. Evidence for pulmonary release of 5-hydroxyeicosatetraenoic acid (5-HETE) during endotoxemia in unanesthetized sheep. Prostaglandins 23: 459 - 468, 1982.

22. Snapper, J. R., Bernard, G. R., Hinson, J. M., Loyd, J. E., Ogletree, M. L., Brigham, K. L. Endotoxemia induced leukopenia in sheep: Correlation with lung vascular permeability and hypoxemia but not with pulmonary hypertension. Am. Rev. Resp. Dis. 127: 306 - 309, 1983.

23. Loyd, J. E., Newman, J. H., English, D., Ogletree, M. L. Meyrick, B. O., Brigham, K. L. Lung vascular effects of phorbol myristate acetate in awake sheep. J. Appl. Physiol. 54: 267 - 276, 1983.

24. Snapper, J. R., Hutchison, A. A., Ogletree, M. L., Brigham, K. L. Effects of cyclooxygenase inhibitors on the alterations in lung mechanics caused by endotoxemia in the unanesthetized sheep. J. Clin. Invest. 72: 63 - 76, 1983.

25. Rojas, J., Larsson, L. E., Ogletree, M. L., Brigham, K. L., Stahlman, M. T. Effects of cyclooxygenase inhibition on the response to group B streptococcal toxin in sheep. Ped. Res. 17: 107 - 110, 1983.

26. Brigham, K. L., Ogletree, M., Snapper, J., Hinson, J., Parker, R. Prostaglandins and lung injury. Chest 835: 705 - 725, 1983.

27. Newman, J. H., Loyd, J. E., Ogletree, M. L., Meyrick, B. O., Brigham, K. L. Cyclooxygenase inhibition during phorbol-induced granulocyte stimulation in awake sheep. J. Appl. Physiol. 56: 999 - 1007, 1984.

28. Newman, J. H., Loyd, J. E., English, D. K., Ogletree, M. L. Fulkerson, W. J., Brigham, K. L. Effects of breathing 100% oxygen on lung vascular function and lung lymph chemotactic activity in awake sheep. J. Appl. Physiol. 54: 1379 - 1386, 1983.

29. Ogletree, M. L. Roles of arachidonic acid metabolites in endotoxin induced pulmonary edema. Seminars in Resp. Med. 4: 303 - 307, 1983.

30. Hutchison, A. A., Ogletree, M. L., Palme, C. J. H., Leheup, B. P., Barrett, J. M., Fleischer, A. C., Stahlman, M. T., Brigham, K. L. Plasma 6-keto prostaglandin $F_{1\alpha}$ and thromboxane B_2 in sick preterm neonates. Prostaglandins, Leukotrienes and Medicine 18: 163 - 181, 1985.

31. Hinson, J. M., Hutchison, A. A., Ogletree, M. L., Brigham, K. L., Snapper, J. R. Effect of granulocyte depletion on altered lung mechanics after endotoxemia in sheep. J. Appl. Physiol. 55: 92 - 99, 1983.

32. Begley, C. J., Ogletree, M. L., Meyrick, B. O., Brigham, K. L. Modification of pulmonary responses to endotoxemia in awake sheep by steroidal and nonsteroidal anti-inflammatory agents. Am. Rev. Resp. Dis. 130: 1140 - 1146, 1984.

33. Ogletree, M. L., Begley, C. J., King, G. A., Brigham, K. L. Influence of steroidal and nonsteroidal anti-inflammatory agents on accumulation of arachidonic acid metabolites in plasma and lung lymph after endotoxemia in awake sheep: Measurements of prostacyclin and thromboxane metabolites and 12-HETE. Am. Rev. Resp. Dis. 133: 55 - 61, 1986.

34. Hutchison, A. A., Ogletree, M. L., Snapper, J. R., Brigham, K. L. Effect of endotoxemia on hypoxic pulmonary vasoconstriction in unanesthetized sheep: Role of prostaglandins. J. Appl. Physiol. 58: 1463 - 1468, 1985.

35. Rojas, J., Palme, C., Ogletree, M. L., Hellerqvist, C. G., Brigham, K. L., Stahlman, M. T. Effects of methylprednisolone on the response to group B streptococcal toxin in sheep. Ped. Res. 18: 1141 - 1144, 1984.

36. Bernard, G. R., Lucht, W. D., Niedermeyer, M. E., Snapper, J. R., Ogletree, M. L., Brigham, K. L. Effect of N-acetylcysteine on the pulmonary response to endotoxin in the awake sheep and upon in vitro granulocyte function. J. Clin. Invest. 73: 1772 - 1784, 1984.

37. Snapper, J. R., Hinson, J. M., Jr., Hutchison, A. A., Lefferts, P. L., Ogletree, M. L., Brigham, K. L. Effects of platelet depletion on the unanesthetized sheep's pulmonary response to endotoxin. J. Clin. Invest. 74: 1782 - 1791, 1984.

38. Henry, C. L., Ogletree, M. L., Brigham, K. L., Hammon, J. W. Thromboxane A_2 mediates the pulmonary vascular response to endotoxin. Surg. Forum 35: 134 - 136, 1984.

39. Ogletree, M. L., Harris, D. N., Greenberg, R., Haslanger, M. F., Nakane, M. Pharmacological actions of SQ 29,548, a novel selective thromboxane antagonist. J. Pharmacol. Exp. Therap. 234: 435 - 441, 1985.

40. O'Keefe, E. H., Greenberg, R., Ogletree, M. L. Effects of a thromboxane synthetase inhibitor and a thromboxane antagonist on release and activity of thromboxane A_2 and prostacyclin in vitro. Prostaglandins 29: 785 - 798, 1985.

41. Meyrick, B. O., Niedermeyer, M. E., Ogletree, M. L., Brigham, K. L. Sustained pulmonary hypertension and increased vasoreactivity caused by repeated indomethacin treatment in sheep. J. Appl. Physiol. 59: 443 - 452, 1985.

42. Hall, S. E., Han, W., Haslanger, M. F., Harris, D. N., Ogletree, M. L. 9,11-Epoxy-9-homo-14-oxaprosta-5-enoic acid derivatives. Novel inhibitors of fatty acid cyclooxygenase. J. Med. Chem. 29: 2335 - 2347, 1986.

43. Ashton, J. H., Schmitz, J. M., Campbell, W. B., Ogletree, M. L., Raheja, S., Taylor, A. L., Fitzgerald, C., Buja, L. M., Willerson, J. T. Inhibition of cyclic flow variations in stenosed canine coronary arteries by thromboxane A_2/prostaglandin H_2 antagonists. Circ. Res. 59: 568 - 578, 1986.

44. Harris, D. N., Phillips, M. B., Michel, I. M., Goldenberg, H. J., Steinbacher, T. E., Ogletree, M. L., Hall, S. E. Inhibition of prostaglandin biosynthesis by SQ 28,852, a 7-oxabicyclo [2.2.1] heptane analog. Prostaglandins 31: 651 - 667, 1986.

45. Ogletree, M. L. Overview of physiological and pathophysiological effects of thromboxane A_2. Fed. Proc. 46: 133 - 138, 1987.

46. Ogletree, M. L., Harris, D. N., Heran, C. L., Phillips, M. B., Michel, I. M., Goldenberg, H. J. Antithrombotic effects of the thromboxane A_2 antagonist , SQ 28,668, *in vitro* and in the coronary circulation *in vivo*. Eicosanoids 1: 85 - 91, 1988.

47. Ashton, J. H., Ogletree, M. L., Michel, I.M., Golino, P., McNatt, J.M., Taylor, A. L., Raheja, S., Schmitz, J., Buja, M., Campbell, W. B., Willerson, J. T. Cooperative mediation by serotonin S_2 and thromboxane A_2/prostaglandin H_2 receptor activation of cyclic flow variations in dogs with severe coronary artery stenoses. Circulation 76: 952 - 959, 1987.

48. Schumacher, W. A., Adams, H. D., Ogletree, M. L. Effect of the thromboxane A_2 receptor antagonists, SQ 28,668 and SQ 29,548, on the pulmonary hypertensive response to endotoxemia in swine. Pharmacology 34: 301 - 308, 1987.

49. Ogletree, M. L., Snapper, J. R., Brigham, K. L. Direct and indirect effects of leukotriene D_4 on the lungs of unanesthetized sheep. Respiration 51: 256 - 265, 1987.

50. Das, J., Vu, T., Harris, D. N., Ogletree, M. L. Synthesis and pharmacological evaluation of 5,6-Exo-epoxy-7-oxabicyclo[2.2.1]heptane derivatives. J. Med. Chem. 31: 930 - 935, 1988.

51. Hedberg, A., Hall, S. E., Ogletree, M. L., Harris, D. N., Liu, E. C.-K. Characterization of [5,6-^{3}H]-SQ 29,548 as a highly specific radioligand, binding to thromboxane A_2/prostaglandin H_2-receptors in human platelets. J. Pharmacol. Exp. Therap. 245: 786 - 792, 1988.

52. Harris, D. N., Hall, S. E., Hedberg, A. H., Ogletree, M. L. 7-Oxabicyclo-heptane analogs: Modulators of the arachidonate cascade. Drugs of the Future 13: 153 - 169, 1988.

53. Schumacher, W. A., Goldenberg, H. J., Harris, D. N., Ogletree, M. L. Effect of thromboxane receptor antagonists on renal artery thrombosis in the cynomolgus monkey. J. Pharmacol. Exp. Therap. 243: 460 - 466, 1987.

54. Schumacher, W. A., Heran, C. L., Goldenberg, H. J., Harris, D. N., Ogletree, M. L. Magnitude of thromboxane receptor antagonism necessary for antithrombotic activity in monkeys. Amer. J. Physiol. 256: H726 - H734, 1989.

55. Schumacher, W. A., Steinbacher, T. E., Allen, G. T., Ogletree, M. L. Role of thromboxane receptors in Forssman shock in guinea pigs. J. Appl. Physiol. 67: 44-51, 1989.

56. Ogletree, M. L., Allen, G. T. Interspecies differences in thromboxane receptors: Studies in rat and guinea pig smooth muscles. J. Pharmacol. Exp. Therap. 260: 789 - 794, 1992.

57. Grover, G. J., Hedberg, A., Ogletree, M. L. Direct myocardial effects of the thromboxane A_2/prostaglandin H_2 agonists U-46619 and SQ 26,655 under ischemic and nonischemic conditions. Pharmacology 41: 1 - 15, 1990.

58. Hall, S. E., Han, W. C., Harris, D. N., Hedberg, A., Ogletree, M. L. 9,11-Epoxy-9-homo-14-thiaprost-5-enoic acid derivatives - potent thromboxane A_2 antagonists. J. Med. Chem. 32: 974-984, 1989.

59. Bech, F. R., Cronenwett, J. L., McDaniel, M. D., Ogletree, M. L., Freeman, D. H. The effect of thromboxane receptor blockade versus thromboxane synthase inhibition on canine arterial graft patency. J. Vasc. Surg. 12: 119 - 125, 1990.

60. Montalescot, G., Lowenstein, E., Ogletree, M. L., Greene, E. M., Robinson, D. R., Hartl, K., Zapol, W. M. Thromboxane receptor blockade prevents heparin-protamine-induced pulmonary hypertension in awake sheep. Circulation 82: 1765 - 1777, 1990.

61. Schumacher, W. A., Heran, C. L., Allen, G. T., Ogletree, M. L. Leukotrienes cause mesenteric vasoconstriction and hemoconcentration in rats without activating thromboxane receptors. Prostaglandins 38: 335 - 344, 1989.

62. Schumacher, W. A., Heran, C. L., Hartl, K. S., Ogletree, M. L. Activity of the short-acting thromboxane receptor antagonist, SQ 30,741, in thrombolytic and vasospastic models in monkeys. J. Pharmacol. Exp. Therap. 253: 841 - 845, 1990.

63. Das, J., Hall, S. E., Nakane, M., Haslanger, M. F., Reid, J. A., Garber, D., Truc, V. C., Harris, D. N., Hedberg, A., Ogletree, M. L. 9,11-Epoxy-9-homo-prosta-5-enoic acid analogs as thromboxane A_2 antagonists. J. Med. Chem. 33: 1741 - 1748, 1990.

64. Nakane, M., Reid, J. A., Han, W.-C., Das, J., Truc, V. C., Haslanger, M. F., Garber, D., Harris, D. N., Hedberg, A., Ogletree, M. L., Hall, S. E. 7-Oxabicyclo[2.2.1]heptyl carboxylic acids as thromboxane antagonists: Aza ω-chain analogs. J. Med. Chem. 33: 2465 - 2476, 1990.

65. Schumacher, W. A., Heran, C. L., Ogletree, M. L. Protamine-induced pulmonary hypertension in heparinized monkeys and pigs is inhibited by the thromboxane receptor antagonist SQ 30,741. Eicosanoids 3: 87 - 93, 1990.

66. Henry, C. L., Ogletree, M. L., Brigham, K. L., Hammon, J. W. Attenuation of the pulmonary vascular response to endotoxin by a thromboxane synthesis inhibitor (UK-38,485) in unanesthetized sheep. J. Surg. Res. 50: 77 - 81, 1991.

67. Schumacher, W. A., Steinbacher, T. E., Allen, G. T., Ogletree, M. L. Role of thromboxane receptor activation in the bronchospastic response to endothelin. Prostaglandins 40: 71 - 79, 1990.

68. Pettigrew, L. C., Hazle, J. D., Gutierrez, G., Smith, C. D., Ogletree, M. L. Correction of ischemic brain acidosis with SQ 29,548 / 1-benzylimidazole. Neurol. Res. 14: 335 - 339, 1992.

69. Ogletree, M. L., O'Keefe, E. H., Durham, S.K., Rubin, B., Aberg, G. Gastroprotective effects of thromboxane receptor antagonists. J. Pharmacol. Exp. Therap. 263: 374 - 380, 1992.

70. Misra, R. N., Brown, B. R., Sher, P. M., Patel, M. M., Hall, S. E., Han, W. C., Barrish, J. C., Floyd, D. M., Sprague, P. W., Harris, D. N., Hedberg, A., Schumacher, W. A., Webb, M. L., DiDonato, G. C., Morrison, R. A., Ridgewell, R. E., White, R. E., Ogletree, M. L. Thromboxane receptor antagonist BMS-180291: A new pre-clinical lead. Bioorg. Med. Chem. Lett. 2: 73 - 76, 1992.

71. Harris, D. N., Michel, I. M., Goldenberg, H. J., Hartl, K. S., Allen, G. T., Steinbacher, T. E., Schumacher, W. A., Han, W.-C., Hall, S. E., Floyd, D. M., Ogletree M. L. Pharmacological characterization of potent, long acting thromboxane receptor antagonists, SQ 33,261 and SQ 33,552. J. Pharmacol. Exp. Therap. 261: 131 - 137, 1992.

72. Vesterqvist, O., Sargent, C. A., Taylor, S. C., Newburger, J., Tymiak, A. A., Grover, G. J., Ogletree M. L. Quantitation of lysophosphatidylcholine molecular species in rat cardiac tissue. Analytical Biochemistry 204: 72 - 78, 1992.

73. Sargent, C.A., Vesterqvist, O., Sleph, P.G., Dzwonczyk, S., Michel, I.M., Conder, M.L., McCullough, J.R., Ogletree, M.L., Grover, G.J. Effect of the phospholipase inhibitors quinacrine and 7,7-dimethyleicosadienoic acid in isolated globally ischemic rat hearts. J. Pharmacol. Exp. Therap. 262: 1161 - 1167, 1992.

74. Ogletree, M.L., Harris, D.N., Schumacher, W.A., Webb, M.L., Misra, R.N. Pharmacological profile of BMS 180,291: A potent, long-acting, orally active thromboxane A_2 / prostaglandin endoperoxide receptor antagonist. J. Pharmacol. Exp. Therap. 264: 570 - 578, 1993.

75. Schumacher, W.A., Steinbacher, T.E., Youssef, S., Ogletree, M.L. Antiplatelet activity of the long-acting thromboxane receptor antagonist BMS 180,291 in monkeys. Prostaglandins 44: 389 - 397, 1992.

76. Sargent, C.A., Vesterqvist, O., Ogletree, M.L., Grover, G.J. Effects of endogenous and exogenous lysophosphatidylcholine in isolated perfused rat hearts. J. Mol. Cell Cardiol., 25: 905 - 913, 1993.

77. Phillipson, D.W., Tymiak, A.A., Tuttle, J.G., Hartl, K.S., Harper, T.W., Bolgar, M.S., Allen, G.T., Ogletree, M.L. Isolation and identification of lysophosphatidyl cholines as endogenous modulators of thromboxane receptors. J. Lipid Mediators 7: 155 - 167, 1993.

78. Schumacher, W.A., Heran, C.L., Steinbacher, T.E., Youssef, S., Ogletree, M.L. Superior activity of a thromboxane receptor antagonist compared to aspirin in rat models of arterial and venous thrombosis. J. Cardiovasc. Pharmacol. 22: 526 - 533, 1993.

79. Schumacher, W.A., Steinbacher, T.E., Heran, C.L., Seiler, S.M., Michel, I.M., Ogletree, M.L. Comparison of thrombin active site and exosite inhibitors and heparin in experimental models of arterial and venous thrombosis and bleeding. J. Pharmacol. Exp. Therap. 267: 1237 - 1242, 1993.

80. Misra, R.N., Brown, B.R., Sher, P.M., Patel, M.M., Hall, S.E., Han, W.C., Barrish, J.C., Kocy, O., Harris, D.N., Goldenberg, H.J., Michel, I.M., Schumacher, W.A., Webb, M.L., Monshizadegan, H., Ogletree, M.L. Interphenylene 7-oxabicyclo[2.2.1]heptane oxazoles. Exceptionally potent, selective and long-acting thromboxane A_2 receptor antagonists. J. Med. Chem. 36: 1401 - 1417, 1993.

81. Gomoll, A.W., Ogletree, M.L. Myocardial salvage efficacy of a thromboxane receptor antagonist, SQ 30,741, in relation to ex vivo inhibition of platelet function in the ferret. Prostaglandins 46: 233 - 242, 1993.

82. Vesterqvist, O., Sargent, C.A., Grover, G.A., Warrack, B.M., DiDonato, G.C., Ogletree, M.L. Characterization of phospholipase A_2 activity in rabbit myocardium using endogenous phospholipid substrates. Analytical Biochemistry 217: 210 - 219, 1994.

83. Premchandran, R.H., Ogletree, M.L., Fried, J. Synthesis of a thromboxane A_2 receptor antagonist possessing the dioxabicycloheptane nucleus of TxA_2. J. Organic Chem. 58: 5724 - 5731, 1993.

84. Gomoll, A.W., Grover, G.J., Ogletree, M.L. Myocardial salvage efficacy of the thromboxane receptor antagonist, ifetroban, in the ferret and dog. J. Cardiovasc. Pharmacol 24: 960 - 968, 1994.

85. Grover, G.J., Schumacher, W.A., Ogletree, M.L. The thromboxane receptor antagonist, BMS-180291, reduces the severity of pacing-induced ischemia in dogs. J. Cardiovasc. Pharmacol. 24: 493 - 499, 1994.

86. Gomoll, A.W., Ogletree, M.L. Failure of aspirin to interfere with the cardioprotective effects of a thromboxane receptor antagonist, ifetroban, in a ferret model of ischemia and reperfusion injury. Eur. J. Pharmacol. 271: 471 - 479, 1994.

87. Misra, R.N., White, R.E., Ogletree, M.L. Ifetroban Sodium. Drugs of the Future 19: 107 - 110, 1994.

88. Ogletree, M.L., Natarajan, S., Seiler, S.M. Thrombin receptors as drug discovery targets. Perspectives in Drug Discovery and Design 1: 527 - 536, 1994.

89. Gomoll, A.W., Schumacher, W.A., Ogletree, M.L. Dose-related cardioprotection by BMS-180291 in relation to inhibition of ex vivo platelet function and thrombosis in the ferret. Pharmacology 50: 92 - 110, 1995.

90. Grover, G.J., Parham, C.S., Youssef, S., Ogletree, M.L. Protective effects of the serotonin ($5HT_2$) receptor antagonist cinanserin in two canine models of pacing-induced myocardial ischemia. Pharmacology 50: 286 - 297, 1995.

91. Kim, K.S., Moquin, R.V., Qian, L., Morrison, R.A., Seiler, S.M., Roberts, D.G.M., Ogletree, M.L., Youssef, S., Chong, S. Preparation of argatroban analogs with less basic guanidine moiety, and studies of their cell permeability and antithrombin activity. Med. Chem. Res., 377 - 383, 1996.

92. Vesterqvist, O., Sargent, C.A., Grover, G.J., Ogletree, M.L. Myocardial calcium-independent phospholipase A_2 activity during global ischemia in isolated rabbit hearts. Cardiovasc. Res. 31: 932 - 940, 1996.

93. Tesfamariam, B.T., Ogletree, M.L. Dissociation of endothelial cell dysfunction and blood pressure in SHR. Amer. J. Physiol. 269: H189 - H194, 1995.

94. Zhang, R., Ogletree, M.L., Moreland, S. Characterization of thromboxane A_2/prostaglandin endoperoxide receptors in aorta. Eur. J. Pharmacol. 317: 91 - 96, 1996.

95. Das, J., Kimball, S.D., Hall, S.E., Han, W.-C., Iwanowicz, E., Lin, J., Moquin, R.V., Reid, J.A., Sack, J.S., Malley, M.F., Chang, C.Y., Chong, S., Wang-Iverson, D.B., Roberts, D.G.M., Seiler, S.M., Schumacher, W.A., Ogletree, M.L. Molecular design and structure activity relationships leading to the potent, selective and orally active thrombin active site inhibitor BMS-189664. Bioorganic and Medicinal Chemistry Letters 12: 45 – 49, 2002.

96. Das, J., Kimball, S.D., Reid, J.A., Wang, T.C., Lau, W.F., Roberts, D.G.M., Seiler, S.M., Schumacher, W.A., Ogletree, M.L. Thrombin active site inhibitors: chemical synthesis, in vitro and in vivo pharmacological profile of a novel and selective agent BMS-189090 and analogs. Bioorganic and Medicinal Chemistry Letters 12: 41 – 44, 2002.

97. Sutton, J.C., Bolton, S.A., Hartl, K.S., Huang, M.-H., Jacobs, G., Meng, W., Ogletree, M.L., Pi, Z., Schumacher, W.A., Seiler, S.M., Slusarchyk, W.A., Treuner, U., Zahler, R., Zhao, G., Bisacchi, G.S. Synthesis and SAR of 4-carboxy-2-azetidinone mechanism-based tryptase inhibitors. Bioorganic and Medicinal Chemistry Letters 12: 3229 - 3233, 2002.

98. Slusarchyk, W.A., Bolton, S.A., Hartl, K.S., Huang, M.-H., Jacobs, G., Meng, W., Ogletree, M.L., Pi, Z., Seiler, S.M., Sutton, J.C., Treuner, U., Zhao, G., Zahler R., Bisacchi, G.S. Synthesis of potent and highly selective inhibitors of human tryptase. Bioorganic and Medicinal Chemistry Letters 12: 3235 - 3258, 2002.

99. Iwanowicz, E., Kimball, S., Lin, J., Lau, W., Han, W., Wang, T., Roberts, D., Schumacher, W., Ogletree, M., Seiler, S. Retro-binding thrombin active site inhibitors: identification of an orally active inhibitor of thrombin catalytic activity. Bioorganic and Medicinal Chemistry Letters 12: 3183 - 3186, 2002.

100. Wang, X., Feuerstein, G.Z., Xu, L., Wang, H., Schumacher, W.A., Ogletree, M.L., Taub, R., Duan, J.J.-W., Decicco, C.P., Wang, R.-Q.L. Inhibition of tumor necrosis factor-α–converting enzyme by a selective antagonist protects brain from focal ischemic injury in rats. Molecular Pharmacology 65:890–896, 2004.

101. Sutton, J.C., Bolton, S.A., Davis, M.E., Hartl, K.S., Jacobson, B., Mathur, A., Ogletree, M.L., Slusarchyk, W.A., Zahler, R., Seiler, S.M., Bisacchi, G.S. Solid-phase synthesis and SAR of 4-carboxy-2-azetidinone mechanism-based tryptase inhibitors. Bioorganic and Medicinal Chemistry Letters 14: 2233-2239, 2004.

102. Bisacchi, G.S., Slusarchyk, W.A., Bolton, S.A., Hartl, K.S., Jacobs, G., Mathur, A., Meng, W., Ogletree, M.L., Pi, Z., Sutton, J.C., Treuner, U., Zahler, R., Zhao, G., Seiler, S.M. Synthesis of potent and highly selective nonguanidine azetidinone inhibitors of human tryptase. Bioorganic and Medicinal Chemistry Letters 14: 2227-2231, 2004.

103. Wang, X., Cheng, Q., Xu, L., Feuerstein, G.Z., Hsu, M.-Y., Smith, P.L., Seiffert, D.A., Schumacher, W.A., Ogletree, M.L., Gailani, D. Effects of factor IX or XI deficiency on ferric chloride-induced carotid artery occlusion in mice. J. Thromb. Haemostas. 3: 695-702, 2005.

104. Wang, X., Smith, P.L., Hsu, M.-Y., Ogletree, M.L., Schumacher, W.A. Blockade of thrombin-activated fibrinolysis inhibitor (TAFI) by potato carboxypeptidase inhibitor (PCI) is antithrombotic in the ferric chloride-induced vena cava thrombosis model in mice. J. Thromb. Haemostas. 4: 403-410, 2006.

105. Wang, X., Smith, P.A., Hsu, M.-Y., Gailani, D., Schumacher, W.A., Ogletree, M.L., Seiffert, D.A. Effects of factor XI deficiency on ferric chloride-induced vena cava thrombosis in mice. J. Thromb. Haemostas., 4: 1982-1988, 2006.

106. Wong, P.C., Crain, E.J., Watson, C.A., Jiang, X., Hua, J., Bostwick, J.S., Ogletree, M.L., Schumacher, W.A., Rehfuss, R. Platelet aggregometry and receptor binding to predict the magnitude of antithrombotic and bleeding time effects of clopidogrel in rabbits. J. Cardiovasc. Pharmacol. 49: 316-324, 2007.

107. Schumacher, W.A., Bostwick, J.S., Ogletree, M.L., Stewart, A.B., Steinbacher, T.E., Hua, J., Price, L.A., Wong, P.C., Rehfuss, R.P. Biomarker optimization to track the antithrombotic and hemostatic effects of clopidogrel in rats. J. Pharmacol. Exp. Therap. 322: 369-377, 2007.

108. Schumacher, W.A., Seiler, S.E., Steinbacher, T.E., Stewart, A.B., Bostwick, J.S., Hartl, K.S., Liu, E.C., Ogletree, M.L. Antithrombotic and hemostatic effects of a small molecule factor XIa inhibitor in rats. Eur. J. Pharmacol. 570: 167-174, 2007.

109. Welch, C,L., Sun, Y., Arey, B.J., Lemaitre, V., Sharma, N., Ishibashi, M.,Sayers, S., Li, R., Gorelik, A., Pleskac, N., Collins-Fletcher, K., Yasuda, Y.,Bromme, D., D'Armiento, J.M., Ogletree, M.L., Tall, A.R. Spontaneous athero-thrombosis and medial degradation in *Niemann-Pick C1-/-*, *Apoe-/-* mice. Circulation 116: 2444-2452, 2007.

110. Bird, J.E., Giancarli, M.R., Allegretto, N., Barbera, F., Wong, P., Schumacher, W.A., Ogletree, M.L., Seiffert, D. Prediction of the therapeutic index of marketed anti-coagulants and anti-platelet agents by guinea pig models of thrombosis and hemostasis. Thrombosis Res. 123: 146-158, 2008.

111. Wang, W., Walker, N.D., Zhu, L.-J., Wu, W., Ge, L., Gutstein, D.E., Yates, N.A., Hendrickson, R.C., Ogletree, M.L., Cleary, M., Opiteck, G.J., Chen, Z. Quantification of circulating D-dimer by peptide immunoaffinity enrichment and tandem mass spectrometry. Analytical Chem 84: 6891-6898, 2012.

112. Xu, Y., Wu, W., Wang, L., Chintala, M., Plump, A.S., Ogletree, M.L., Chen, Z. Differential profiles of thrombin inhibitors (heparin, hirudin, bivalirudin, and dabigatran) in the thrombin generation assay and thromboelastography in vitro. Blood Coagul Fibrinolysis 24: 332-338, 2013

113. Chao, H., Turdi, H., Herpin, T.F., Roberge, J.Y., Liu, Y., Schnur, D.M., Poss, M.A., Rehfuss, R., Hua, J., Wu, Q., Price, L.A., Abell, L.M., Schumacher, W.A., Bostwick, J.S., Steinbacher, T.E., Stewart, A.B., Ogletree, M.L., Huang, C.S., Chang, M., Cacace, A.M., Arcuri, M.J., Celani, D., Wexler, R.R., Lawrence, R.M. Discovery of 2-(phenoxypyridine)-3-phenylureas as small molecule P2Y1 antagonists. J Med Chem. 56: 1704-1714, 2013.

114. Woodruff, R.S., Xu, Y., Layzer, J., Wu, W., Ogletree, M.L., Sullenger, B.A. Inhibiting the intrinsic pathway of coagulation with a factor XII-targeting RNA aptamer. J Thromb Haemost. 11: 1364-1373, 2013.

115. Xu, Y., Cai, T.Q., Castriota, G., Zhou, Y., Hoos, L., Jochnowitz, N., Loewrigkeit, C., Cook, J.A., Wickham, A., Metzger, J.M., Ogletree, M.L., Seiffert, D.A., Chen, Z. Factor XIIa inhibition by Infestin-4: in vitro mode of action and in vivo antithrombotic benefit. Thromb Haemost. 111:694-704, 2014.

116. Blizzard, T.A., Singh, S., Patil, B., Chidurala, N., Komanduri, V., Debnath, S., Belyakov, S., Crespo, A., Struck, A., Kurtz, M., Wiltsie, J., Shen, X., Sonatore, L., Arocho, M., Lewis, D., Ogletree, M., Biftu, T. Heterocyclic core analogs of a direct thrombin inhibitor. Bioorg Med Chem Lett. 24: 1111-1115, 2014.

117. Cai, T.-Q., Wu, W., Shin, M.K., Xu, Y., Jochnowitz, N., Zhou, Y., Hoos, L., Bentley, R., Strapps, W., Thankappan, A., Metzger, J.M., Ogletree, M.L., Tadin-Strapps, M., Seiffert, D.A., Chen, Z. Factor XII full and partial null in rat confers robust antithrombotic efficacy with no bleeding. Blood Coagulation and Fibrinolysis 26: 893-902, 2015.

118. Friedman, E., Ogletree, M.L., Haddad. E. and Boutaud, O. Understanding the role of prostaglandin E_2 in regulating human platelet activity in health and disease. Thrombosis Research 136: 493-503, 2015.

119. Simmers, M.B., Cole, B.K., Ogletree, M.L., Chen, Z., Xu, Y., Kong, L., Mackman, N., Blackman, B.R., Wamhoff, B.R. Hemodynamics associated with atrial fibrillation directly alters thrombotic potential of endothelial cells. Thrombosis Research 143: 34–39, 2016.

120. Pulley, J.M., Jerome, R.N., Ogletree, M.L., Bernard, G.R., Lavieri, R.R., Zaleski, N.M., Hong, C., Shirey-Rice, J.K., Arteaga, C.L., Holroyd, K.J., Cook, R.S. Motivation for launching a Cancer Metastasis Inhibition (CMI) program. (In Preparation for Clinical Cancer Research)

Book Chapters:

1. Lefer, A. M., Ogletree, M. L. Beneficial actions of glucocorticoids and prostaglandins in myocardial ischemia. Acute and Long Term Management of Myocardial Ischemia, Hjalmarson A, Wilhelser L (eds) A. Lindgren and Sons, A. B., Molndal, Sweden, pp. 229-237, 1978.

2. Lefer, A. M., Ogletree, M. L. Preservation of ischemic myocardial tissue by prostaglandins. Prostaglandins in Cardiovascular and Renal Function, Scriabine A, Lefer AM, Kuehl Jr FA (eds), Spectrum Publications, New York, pp. 175-188, 1980.

3. Ogletree, M. L., Smith, J. B., Lefer, A. M. Cardiac and coronary vascular actions of prostaglandins in cats. Prostaglandins in Cardiovascular and Renal Function, Scriabine A, Lefer AM, Kuehl Jr FA (eds), Spectrum Publications, New York, pp. 145-158, 1980.

4. Frolich, J. C., Ogletree, M. L., Peskar, B. A., Brigham, K. L. Pulmonary hypertension correlated to pulmonary thromboxane synthesis. Advances in Prostaglandin and Thromboxane Research: Vol. 7, Samuelsson B, Ramwell PW, Paoletti R (eds), Raven Press, New York, pp. 745-750, 1980.

5. Lefer, A. M., Ogletree, M. L., Smith, E. F. Role of prostaglandins in acute myocardial ischemia. Prostaglandins and Thromboxanes in the Cardiovascular System and in Gynaecology and Obstetrics, Forster W (ed), V.E.B. Gustav Fischer Verlag, Jena, pp. 15 - 20, 1981.

6. Ogletree, M. L., Schlesinger, K., Nettleman, M., Hubbard, W. C. Measurement of 5-hydroxyeicosatetraenoic acid (5-HETE) by GC-MS. Prostaglandins and Arachidonate Metabolites - Methods in Enzymology: Vol. 86, Lands WEM, Smith WL (eds), Academic Press, New York, pp. 607 - 612, 1982.

7. Brigham, K. L., Newman, J. H., Snapper, J. R., Ogletree, M. L. Metabolites of arachidonic acid in the pathophysiology of the pulmonary circulation. Prostaglandins and the Cardiovascular System, Oates JA (ed), Raven Press, New York, pp. 355 - 364, 1982.

8. Brigham, K. L., Begley, C. J., Bernard, G. R., Hutchison, A. A., Loyd, J. E., Lucht, W. D., Meyrick, B. O., Newman, J. H., Niedermeyer, M. E., Ogletree, M. L., Sheller, J. R., Snapper, J. R. Septicemia and lung injury. Clinics in Lab. Med. 3: 719 - 744, 1983.

9. Ogletree, M. L. Basic circulatory actions of leukotrienes. Leukotrienes in Cardiovascular and Pulmonary Function, Lefer AM, Gee MH (eds), Alan R. Liss, Inc., pp. 13 - 15, 1985.

10. Nakane, M., Reid, J. A., Haslanger, M. F., Garber, D. P., Harris, D. N., Ogletree, M. L., Greenberg, R. The aza substituted ω-side chain modifications of 7-oxabicyclo [2.2.1] heptane TxA_2 receptor antagonists: structure activity relationships. Kyoto Conference on Prostaglandins, Hayaishi O, Yamamoto S (eds), Raven Press, New York, pp. 291 - 293, 1985.

11. Ogletree, M. L. Studies with SQ 30,741: A thromboxane receptor antagonist. Proceedings of the 2nd International Conference on Leukotrienes and Prostanoids in Health and Disease. In: New Trends in Lipid Mediators Research, Zor R, Danon A (eds), Basel, Karger, vol 3, pp 89 - 93, 1989.

12. Ogletree, M.L. Thrombin receptor mediated signaling in endothelial cells. In: The Endothelial Cell in Health and Disease, Born GVR, Vane JR, Welzel D (eds), Schattauer-Verlag, pp 85 - 96, 1995.

Selected Abstracts:

1. Ogletree, M.L., O'Keefe, E.H., Michel, I.M., Harris, D.N. Target tissues for thromboxane receptor mediated increases in vascular permeability. Circulation 78: II-330, 1988.

2. Warrack, B.M., Taylor, S.C., Vesterqvist, O., Ogletree, M.L., DiDonato G.C. LC-MS and LC-MS-MS characterization of lysophosphatidylcholines and acylcarnitines present in the ischemic region of dog hearts. Proc 40th ASMS Conf on Mass Spectrometry and Allied Topics, Washington, D.C., June 1-5, 1992.

3. Ogletree, M.L. Coronary contraction induced by 8-epi $PGF_{2\alpha}$ is independent of $PGF_{2\alpha}$ receptors and is mediated by thromboxane receptors. Circulation 86: I-298, 1992.

4. Swanson, B.N., Manning, J.A., Ogletree, M.L., Uderman, H., Skoloda, S.J., Delaney, C.L., Liao, W.-C. Effect of BMS-180291, a long-acting thromboxane A_2 receptor antagonist, on platelet function in healthy men. Clin. Pharm. Therap. 55: 202, 1994.

5. Vesterqvist, O., Sargent, C., Grover, G.J., Ogletree, M.L. Endogenous lysophospholipid levels show no increase in phospholipase A_2 activity during cardiac ischemia. Prostaglandins, Leukotrienes and Essential Fatty Acids 55 (Suppl 1): 130, 1996.

6. Arey, B.J., Youssef, S., Feyen, J.H.M., Normandin, D., Ogletree, M.L. Plasma levels of thrombotic biomarkers are increased in animal models of diabetes. Diabetes 54 (Suppl 1): A164-A165, 2005

7. Arey, B.J., Normandin, D., Feyen, J.H.M., Youssef, S., Ogletree, M.L. Elevation of thrombotic biomarkers reveals the prothrombotic state of genetically diabetic (db/db) and obese (ob/ob) mice. J. Thromb. Haemost. 3 (Suppl 1): P2183, 2005.

8. Schumacher, W., Wong, P., Seiler, S., Steinbacher, T., Stewart, A., Hartl, K., Liu, E., Crain, E., Watson, C., Staus, A., Ogletree, M. Antithrombotic activity of a small molecule factor XIa inhibitor in rats and rabbits with limited effects on bleeding time. J. Thromb. Haemost. 3 (Suppl 1): P1228, 2005.

9. Schumacher, W.A., Rehfuss, R.P., Bostwick, J., Price, L., Hua, J., Wong, P.C., Ogletree, M.L. Ex vivo biomarkers of antiplatelet effects differ in their sensitivity to clopidogrel and in predicting its in vivo antithrombotic activity in experimental models. Eur. Heart J. 27 (Eur. Soc. Cardiol. Abstract Suppl): 751, 2006.

10. Youssef, S., Normandin, D.E., Seiler, S., Mukherjee, R., Cheng, P.T., Ogletree, M.L., Arey, B.N. Elevated thrombotic biomarkers in diabetic mice are lowered by PPAR-alpha selective agonists. Eur. Heart J. 27 (Eur. Soc. Cardiol. Abstract Suppl): 971, 2006.

11. Wong, P.C., Crain, E.J., Watson, C.A., Jiang, X., Bostwick, J.S., Thibault, C., Ruel, R., Rehfuss, R., Schumacher, W.A., Ogletree, M.L. Differential effects of P2Y12 versus P2Y1 antagonism on thrombosis, bleeding and ex vivo platelet aggregation in rabbits. Circulation, Am. Heart Assoc. Abstract #1310, 2006.

12. Wang, X., Smith, P.L., Hsu, M., Ruel, R., Rehfuss, R., Wong, P.C., Ogletree, M.L., Schumacher, W.A. P2Y1 receptor deficiency or pharmacological blockade protects mice from ferric chloride-induced vena cava thrombosis. Circulation, Am. Heart Assoc. Abstract #1311, 2006.

13. Wong, P.C., Kettner, C., Mersinger, L., Watson, C.A., Crain, E.J., Harpel, M., Schumacher, W.A., Ogletree, M.L., Rendina, A. Nonpeptide factor XIa inhibitor. In vitro kinetic evaluation and in vivo studies of BMS-262084. Circulation, Am. Heart Assoc. Abstract #631, 2006.

14. Wong, P.C., Watson, C.A., Crain, E.J., Luettgen, J.M., Ogletree, M.L., Wexler, R.R., Lam, P.Y.S., Pinto, D.J., Knabb, R.M. Effects of the factor Xa inhibitor apixaban on venous thrombosis and hemostasis in rabbits. Blood 108: Am. Soc. Hematol. Abstract #917, 2006.

15. Wong, P.C., Crain, E.J., Watson, C.A., Jiang, X., Bostwick, J.S., Rehfuss, R., Schumacher, W.A., Ogletree, M.L. Platelet aggregometry and receptor binding to predict the magnitude of antithrombotic and bleeding time effects of clopidogrel in rabbits. J. Am. Coll. Cardiol. 49 (Suppl. A): Abstract #815-8, 2007.

16. Ogletree, M.L., Wong, P.C., Schumacher, W.A., Rehfuss, R.P. Clopidogrel produces distinct dose-response relationships for inhibition of platelet aggregation (IPA) and antithrombotic efficacy measured in rats and rabbits. J. Thromb. Haemost. 5 (Suppl 2): P-T-345, 2007.

17. Wong, P.C., Watson, C.A., Crain, E.J., Ogletree, M.L., Wexler, R.R., Lam, P.Y.S., Pinto, D.J., Knabb, R.M. Potent antithrombotic activity of apixaban, a direct factor Xa inhibitor, with minimum bleeding time effect in rabbit models of arterial thrombosis and hemostasis. J. Thromb. Haemost. 5 (Suppl 2): P-T-656, 2007.

18. Luettgen, J.M., Wang, Z., Seiffert, D.A., Rendina, A.R., Knabb, R.M., Ogletree, M.L. Inhibition of measured thrombin generation in human plasma by apixaban: a predictive mathematical model based on experimentally determined rate constants. J. Thromb. Haemost. 5 (Suppl 2) P-T-633, 2007.

19. Chen, Z., Wu, W., Xu, Y., Ogletree, M.L., Plump, A.S., Graziano, M., Wang, L. A comparison of inhibitors for thrombin, FXa, FXIa, and FXIIa in whole blood coagulation and fibrinolysis using thromboelastography. Blood 118: Am. Soc. Hematol. Abstract #2256, 2011.

20. Wamhoff, B.R., Simmers, M.B., Chen, Z., Xu, Y., Kong, L.-J., Cole, B., Pryor, A.W., Berry, D.J., Day, N., Blackman, B.R., Ogletree, M.L. Atrial fibrillation-induced changes in left atrial hemodynamics directly impact the thrombotic potential of human primary endothelial cell cultures. ATVB 33: A73, 2013.

21. Chen, Z., Wu, W., Ge, L., Ichetovkin, M., Desai, K., Wang, W., Xu, Y., Ogletree, M.L., Seiffert, D.A. Biomarkers of hemostasis and thrombosis in hemophilia A and B patients. ATVB 34: A568, 2014.